GSK 2292767

Drug Profile

GSK 2292767

Alternative Names: GSK2292767

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Indazoles; Morpholines; Oxazoles; Small molecules; Sulfonamides
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Asthma

Most Recent Events

  • 03 Feb 2017 GlaxoSmithKline plans a phase I trial in Asthma (In volunteers) in USA (NCT03045887)
  • 01 Aug 2015 Preclinical trials in Asthma in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top